Annexon Inc是一家临床阶段的生物制药公司。该公司致力于为患有严重补体介导的自身免疫性疾病、神经退行性疾病和眼科疾病的患者开发补体药物。它的产品线包括三个临床阶段的资产,跨越三个治疗专营权:自身免疫、神经退行性病变和眼科。其主要候选基因ANX005是一种单克隆抗体,可用于多种自身免疫适应症的静脉注射。ANX005正在接受治疗格林-巴利综合征患者的II/III期临床试验和治疗温热性自身免疫性溶血性贫血患者的II期试验的评估。ANX009临床候选者是一种抗原结合片段的皮下制剂,在一期试验中进行评估。该公司还在开发ANX005,该产品正在亨廷顿病和肌萎缩侧索硬化症的II期试验中。该公司的ANX007计划是一个由Fab制定的计划。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Thomas G. Wiggans | Independent Chairman | 2021 | 74 |
| Douglas E. Love | CEO, President & Director | 2014 | 58 |
| Ted Yednock | Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board | 2023 | 68 |
| Muneer Ahmad Satter | Independent Director | 2014 | 65 |
| Jung E. Choi | Independent Director | 2020 | 56 |
| William D. Waddill | Independent Director | 2021 | 69 |
| P. Hugh Willison | Member of Scientific Advisory Board | - | - |
| Thomas P. Maniatis | Member of Scientific Advisory Board | - | 83 |
| David M. Holtzman | Member of Scientific Advisory Board | - | - |
| Stephen L. Hauser | Member of Scientific Advisory Board | - | - |
| Jeffrey Goldberg | Member of Scientific Advisory Board | - | - |
| Beth Stevens | Member of Scientific Advisory Board | - | - |
| William H. Carson | Independent Director | 2021 | 66 |
| Bettina M. Cockroft | Independent Director | 2022 | 58 |
| William Jones | Independent Director | 2025 | 62 |